A phase I study of GTI-2040 (G), an antisense to ribonucleotide reductase (RNR), in combination with high-dose AraC (HiDAC) in acute myeloid leukemia (AML) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results